COMP <GO>
EME vs TMO // REVENUE GROWTH (YOY)
EMCOR Group Inc. (NYSE) VS. Thermo Fisher Scientific Inc (NYSE) • 15-METRIC TALLY: EME 6
— TMO 8
▲ REVENUE GROWTH (YOY) LEADER: EME
LAST: $679.55 (-1.42%) • MKT CAP: $30.41B
revenue-growth
16.60%
LAST: $697.00 (-1.72%) • MKT CAP: $262.22B
revenue-growth
3.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EME VS. TMO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EME | TMO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 19.30% | 41.00% | -21.70 | TMO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 27.50% | 9.30% | +18.20 | EME | /roic <GO> |
| EV/EBITDA & P/E Valuation | 13.4x | 30.4x | -17.00 | EME | /valuation <GO> |
| Free Cash Flow Yield | 1.77% | 2.40% | -0.63 | TMO | /fcf-yield <GO> |
| Operating Margin | 10.10% | 17.40% | -7.30 | TMO | /operating-margins <GO> |
| Net Profit Margin | 7.50% | 15.10% | -7.60 | TMO | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 16.60% | 3.90% | +12.70 | EME | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.15% | 0.24% | -0.09 | TMO | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.73 | 4.50 | +2.23 | EME | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.30% | 6.70% | +0.60 | TMO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.4 | 59.1 | -20.75 | TMO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.13 | 0.94 | +0.19 | EME | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.1x | 36.3x | -16.20 | EME | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $30.41B | $262.22B | -$231.81B | TMO | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EME REV | TMO REV | EME GROSS % | TMO GROSS % | EME FCF | TMO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $16.99B | $44.56B | 19.3% | 44.0% | $537.7M | $6.29B |
| FY 2024 | $14.57B | $42.88B | 19.0% | 44.0% | $752.4M | $7.27B |
| FY 2023 | $12.58B | $42.86B | 44.0% | 44.0% | $333.4M | $6.48B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EME // BETA 1.13
TMO // BETA 0.94